193 related articles for article (PubMed ID: 30821007)
1. Efficacy and safety of Brentuximab Vedotin in advanced cutaneous T-Cell lymphomas patients.
Papadavid E; Kapniari E; Marinos L; Nikolaou V; Oikonomidi A; Georgakopoulos J; Stratigos A; Kouloulias V; Pappa V
J Eur Acad Dermatol Venereol; 2019 May; 33(5):e223-e225. PubMed ID: 30821007
[No Abstract] [Full Text] [Related]
2. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
Shea L; Mehta-Shah N
Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study.
Dummer R; Prince HM; Whittaker S; Horwitz SM; Kim YH; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown L; Sanches JA; Ortiz-Romero PL; Akilov OE; Geskin L; Huen A; Walewski J; Wang Y; Lisano J; Richhariya A; Feliciano J; Zhu Y; Bunn V; Little M; Zagadailov E; Dalal MR; Duvic M
Eur J Cancer; 2020 Jul; 133():120-130. PubMed ID: 32502876
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of brentuximab vedotin plus bendamustine in advanced-stage primary cutaneous T-cell lymphomas.
Dumont M; Ram-Wolff C; Roelens M; Brice P; Peffault de Latour R; Battistella M; Madelaine I; Delyon J; Herms F; Bouaziz JD; Moins-Teisserenc H; Lebbé C; Bagot M; de Masson A
Br J Dermatol; 2019 Dec; 181(6):1315-1317. PubMed ID: 31206589
[No Abstract] [Full Text] [Related]
5. Brentuximab vedotin in multifocal cutaneous anaplastic large cell lymphoma in a patient with human immunodeficiency virus following Hodgkin lymphoma.
Wolf S; Goiriz R; Dhairyawan R; Paige D; Rizvi H; Haroon A; Montoto S
Clin Exp Dermatol; 2019 Jul; 44(5):562-564. PubMed ID: 30430604
[No Abstract] [Full Text] [Related]
6. Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Zinzani PL; Salles G; Moskowitz AJ; Santoro A; Mehta A; Barr PM; Mehta-Shah N; Collins GP; Ansell SM; Brody JD; Domingo-Domenech E; Johnson NA; Cunningham D; Ferrari S; Lisano J; Krajewski J; Wen R; Akyol A; Crowe R; Savage KJ
Blood Adv; 2024 May; 8(10):2400-2404. PubMed ID: 38531062
[No Abstract] [Full Text] [Related]
7. Long term survival, time to next treatment and CD30 expression in patients with advanced CD30
Gosmann J; Stadler R
J Dtsch Dermatol Ges; 2022 Apr; 20(4):514-517. PubMed ID: 35319153
[No Abstract] [Full Text] [Related]
8. Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin.
Şahin M; Miskioğlu M; İnanır I; Akar H; Neşe N; Temiz P; Aydoğdu İ
Turk J Haematol; 2021 Feb; 38(1):85-87. PubMed ID: 33504137
[No Abstract] [Full Text] [Related]
9. Cost-Effectiveness of Brentuximab Vedotin Versus Physician's Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada.
Elsea D; Savage KJ; Lilley C; Lisano J; Liu J; Yu KS
Adv Ther; 2023 May; 40(5):2326-2338. PubMed ID: 36920744
[TBL] [Abstract][Full Text] [Related]
10. Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma.
Van-de-Velde V; Zhou Y
J Cutan Med Surg; 2019; 23(3):319-327. PubMed ID: 30943788
[TBL] [Abstract][Full Text] [Related]
11. RF - Brentuximab as Treatment for CD30
Morgado-Carrasco D; Combalia A; Estrach Panella T
Actas Dermosifiliogr (Engl Ed); 2019 Nov; 110(9):769-770. PubMed ID: 31151669
[No Abstract] [Full Text] [Related]
12. Management of primary cutaneous CD4
Yuan Z; Grass GD; Robinson TJ; Kim S
J Am Acad Dermatol; 2018 Oct; 79(4):772-774. PubMed ID: 29857014
[No Abstract] [Full Text] [Related]
13. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.
Goyal A; Patel S; Goyal K; Morgan EA; Foreman RK
J Cutan Pathol; 2019 Nov; 46(11):823-829. PubMed ID: 31286556
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of APO866 in Patients With Refractory or Relapsed Cutaneous T-Cell Lymphoma: A Phase 2 Clinical Trial.
Goldinger SM; Gobbi Bischof S; Fink-Puches R; Klemke CD; Dréno B; Bagot M; Dummer R
JAMA Dermatol; 2016 Jul; 152(7):837-9. PubMed ID: 27007550
[No Abstract] [Full Text] [Related]
15. Primary cutaneous aggressive epidermotropic cytotoxic CD8
Cyrenne BM; Subtil A; Girardi M; Foss F
Int J Dermatol; 2017 Dec; 56(12):1448-1450. PubMed ID: 29047111
[No Abstract] [Full Text] [Related]
16. Successful treatment with brentuximab vedotin for relapsed and refractory adult T cell leukemia.
Oka S; Ono K; Nohgawa M
Anticancer Drugs; 2020 Jun; 31(5):536-539. PubMed ID: 31934889
[TBL] [Abstract][Full Text] [Related]
17. Highlights in cutaneous T-cell lymphoma from the 60th American Society of Hematology Annual Meeting.
Clin Adv Hematol Oncol; 2019 Feb; 17 Suppl 3(2):1-24. PubMed ID: 31545304
[No Abstract] [Full Text] [Related]
18. Brentuximab vedotin in T-cell lymphoma.
Van Der Weyden C; Dickinson M; Whisstock J; Prince HM
Expert Rev Hematol; 2019 Jan; 12(1):5-19. PubMed ID: 30526166
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma.
Podkonjak T; Cranmer H; Scarisbrick J; McCarthy G; Lilley C; Cheng LI
J Comp Eff Res; 2022 Feb; 11(3):193-202. PubMed ID: 34879742
[No Abstract] [Full Text] [Related]
20. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
Scarisbrick JJ
Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
